Metabolic & Cardiometabolic
GLP-1 receptor agonists decreases major adverse cardiovascular events
In plain terms: Do GLP-1 weight-loss/diabetes drugs actually lower the risk of heart attacks and strokes?
Part of: 💊 GLP-1 Drugs
Yes — across multiple large randomized trials and meta-analyses they cut major cardiovascular events by roughly 12-20%, in people with diabetes and (per SELECT) in obesity without diabetes.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Khera 2024 · J Am Coll Cardiol | observational | mixed | moderate | LEGEND-T2DM federated real-world analysis: GLP-1RA broadly favorable for CV outcomes vs other 2nd-line agents; non-randomized. |
| Amorim 2026 · Chronic Dis Transl Med | observational | supports | moderate | Review synthesizing CVOTs (LEADER/SUSTAIN-6/SELECT/REWIND) as consistent MACE reduction; mechanism via weight/lipids/inflammation. |
| Sattar 2021 · Lancet Diabetes Endocrinol | meta-analysis | supports | high | Updated MA of 8 CVOTs: MACE HR 0.86 (14% reduction); all-cause mortality and kidney outcomes also reduced. |
| McGuire 2025 · N Engl J Med | RCT | supports | high | SOUL: oral semaglutide reduced MACE in high-risk T2D (HR 0.86, 95% CI 0.77-0.96); extends benefit to oral formulation. |
| Gerstein 2019 · Lancet | RCT | supports | high | REWIND: dulaglutide reduced MACE in broad T2D pop (mostly primary prevention) HR 0.88 (95% CI 0.79-0.99). |
| Kristensen 2019 · Lancet Diabetes Endocrinol | meta-analysis | supports | high | MA of 7 CVOTs (n=56,004): MACE HR 0.88 (12% reduction); CV death, stroke, MI, HF admission, kidney all lower. |
| Ritsinger 2026 · Diabetes Obes Metab | observational | supports | moderate | Swedish real-world SELECT-like obesity cohort: high baseline CV event rates support meaningful preventive potential of semaglutide. |
| Maggioni 2026 · Int J Cardiol | observational | supports | low | Eligibility analysis citing SELECT+SOUL as establishing MACE reduction; real-world cohorts differ from trials. |
| Marso 2016 · N Engl J Med | RCT | supports | high | SUSTAIN-6: semaglutide cut MACE in T2D (HR 0.74, 95% CI 0.58-0.95), driven by nonfatal stroke; pre-specified noninferiority trial. |
| Lincoff 2023 · N Engl J Med | RCT | supports | high | SELECT: in obesity w/o diabetes + CVD, semaglutide 2.4mg cut MACE 20% (HR 0.80, 95% CI 0.72-0.90) over ~40mo. |
| Badve 2025 · Lancet Diabetes Endocrinol | meta-analysis | supports | high | MA incl SELECT/FLOW: GLP-1RA reduce CV and kidney composite outcomes across diabetic and non-diabetic populations. |
| Marso 2016 · N Engl J Med | RCT | supports | high | LEADER: liraglutide reduced MACE in T2D w/ high CV risk (HR 0.87, 95% CI 0.78-0.97); CV death also lower. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.